The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...

The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...

Following the recent approval of nerandomilast tablets for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, the FDA has approved the medication for progressive pulmonary fibrosis as ...

Enhertu showed improved iDFS over Kadcyla in early-stage HER2-positive breast cancer with residual disease post-neoadjuvant ...

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...

Disclaimer: Trastuzumab deruxtecan has not been approved by the FDA for the neoadjuvant or adjuvant setting for early-stage, ...

Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease med Jascayd, Boehringer Ingelheim is already unlocking another patient po | ...

For patients living with HER2-positive metastatic breast cancer, the recent FDA approval of trastuzumab deruxtecan (brand ...

Insmed is discontinuing development of brensocatib in chronic rhinosinusitis without nasal polyps. "Insmed Ends Sinus Drug Development on Failed Study, Acquires Antibody Treatment," at 4:21 p.m. ET, ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.